Baker BROS. Advisors LP Has $1.26 Million Holdings in Sana Biotechnology, Inc. $SANA

Baker BROS. Advisors LP cut its stake in Sana Biotechnology, Inc. (NASDAQ:SANA) by 84.7% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 310,483 shares of the company’s stock after selling 1,720,466 shares during the quarter. Baker BROS. Advisors LP’s holdings in Sana Biotechnology were worth $1,264,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. Vanguard Group Inc. raised its holdings in shares of Sana Biotechnology by 19.9% in the 3rd quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock worth $32,408,000 after buying an additional 1,517,474 shares in the last quarter. State Street Corp raised its holdings in shares of Sana Biotechnology by 20.6% in the 4th quarter. State Street Corp now owns 8,054,841 shares of the company’s stock worth $32,783,000 after buying an additional 1,374,300 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Sana Biotechnology by 20.3% in the 4th quarter. Geode Capital Management LLC now owns 4,118,138 shares of the company’s stock worth $16,763,000 after buying an additional 694,606 shares in the last quarter. Integral Health Asset Management LLC raised its holdings in shares of Sana Biotechnology by 50.0% in the 4th quarter. Integral Health Asset Management LLC now owns 3,000,000 shares of the company’s stock worth $12,210,000 after buying an additional 1,000,000 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Sana Biotechnology by 180.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock worth $7,581,000 after buying an additional 1,375,029 shares in the last quarter. 88.23% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently commented on SANA shares. Morgan Stanley restated an “overweight” rating and set a $12.00 price target on shares of Sana Biotechnology in a research report on Friday, March 13th. Zacks Research lowered Sana Biotechnology from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 3rd. Rodman & Renshaw started coverage on Sana Biotechnology in a research report on Monday, May 11th. They set a “buy” rating and a $16.00 price target on the stock. HC Wainwright decreased their price target on Sana Biotechnology from $9.00 to $7.00 and set a “buy” rating on the stock in a research report on Wednesday, March 4th. Finally, Weiss Ratings lowered Sana Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Sana Biotechnology currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.50.

Sana Biotechnology Price Performance

NASDAQ SANA opened at $3.04 on Thursday. The firm has a market cap of $846.00 million, a PE ratio of -3.27 and a beta of 2.14. Sana Biotechnology, Inc. has a one year low of $2.58 and a one year high of $6.55. The stock’s 50 day simple moving average is $3.20 and its 200 day simple moving average is $3.77.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. As a group, equities analysts expect that Sana Biotechnology, Inc. will post -0.59 earnings per share for the current year.

About Sana Biotechnology

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.